Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods under Section 41

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods to ensure their quality, safety, and efficacy. This legislation provides the framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, through the Therapeutic Goods Administration (TGA). A notable issue the Act was designed to address is the maintenance of high standards for the manufacturing, importation, and distribution of therapeutic goods to protect public health. This legislative framework ensures that only goods meeting prescribed standards are available in the market, thereby safeguarding the health and safety of the Australian public. The policy objective of the Therapeutic Goods Act 1989 is to maintain and improve the health of Australians by regulating therapeutic goods effectively, including the revocation of licenses for manufacturers who no longer meet the required standards, as demonstrated by the revocation of licenses for Vitex Pharmaceuticals Pty Ltd and Ixom Operations Pty Ltd.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Department of Health, governs the regulation of therapeutic goods in Australia. This Act applies to entities involved in the manufacturing, importation, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood and blood components. The scope of the Act is comprehensive, covering a wide range of activities and products that are integral to public health and safety. The Act extends to the whole of Australia, thereby ensuring uniform standards and practices across all states and territories. Notably, the Act includes provisions for the revocation of licences to manufacture therapeutic goods, as evidenced by the revocation of the licences held by Vitex Pharmaceuticals Pty Ltd and Ixom Operations Pty Ltd, which were revoked at the request of the manufacturers. While the primary Act sets out the fundamental principles and requirements, its application and detailed regulations are often supplemented by subordinate instruments, ensuring that the legislation remains adaptable to new challenges and advancements in therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, as referenced in section 41(1)(d), provides the legal framework for the revocation of a Licence to Manufacture Therapeutic Goods. According to this section, the Secretary can revoke a licence if certain conditions are met, and the revocation may occur at the request of the manufacturer. In this particular instance, the Secretary has revoked two licences: one held by Vitex Pharmaceuticals Pty Ltd (LICENCE NO. MI-27102004-LI-000085-1) and the other by Ixom Operations Pty Ltd incorporating Bronson & Jacobs (LICENCE NO. MI-29052007-LI-001879-1). Both licences were revoked at the request of the respective manufacturers. The revocation of these licences means that the entities named are no longer authorised to manufacture therapeutic goods under the authority of these licences. The Act imposes several obligations on the parties or entities that hold a licence to manufacture therapeutic goods. These obligations include ensuring that the manufacturing processes adhere to the standards set out in the Therapeutic Goods Regulations 1990. This includes maintaining appropriate quality control measures, ensuring that the therapeutic goods produced are safe and effective, and complying with any other requirements set out in the Act or the Regulations. Failure to meet these obligations can lead to the revocation of the licence as seen in this case. Breaching the obligations set out in the Therapeutic Goods Act 1989 can have serious consequences. The Act provides for both civil and criminal penalties for non-compliance. Under the Act, a person who contravenes certain provisions can be subject to fines. For example, section 32 of the Act provides that a person who contravenes a direction given under section 31 can be fined up to 50 penalty units for a corporation and up to 10 penalty units for an individual. In addition to financial penalties, the revocation of a licence to manufacture therapeutic goods, as outlined in this notice, can have significant repercussions for a manufacturer’s ability to operate in the industry. This revocation effectively bars the entity from manufacturing therapeutic goods until a new licence is obtained, which may involve meeting stringent regulatory requirements and demonstrating compliance with the Act.